Vienne Seitz, Jed Calata, Ling Mei, Emily R W Davidson
{"title":"Missed Opportunities: A Mixed-Methods Assessment of Disparities in Treatment for Fecal Incontinence.","authors":"Vienne Seitz, Jed Calata, Ling Mei, Emily R W Davidson","doi":"10.1097/SPV.0000000000001619","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>Previous work identified racial disparities in access to fecal incontinence (FI) treatments. However, less is known about patient perspectives of these barriers.</p><p><strong>Objectives: </strong>This study assessed differences in FI symptom severity and treatment utilization between Black and White patients.</p><p><strong>Study design: </strong>This mixed-methods assessment studied adult non-Hispanic Black and White women treated for FI who either did not respond to medical therapy nor received sacral neuromodulation or did not follow up after medical therapy. Structured interviews queried patients about treatments offered and symptom severity.</p><p><strong>Results: </strong>Of the 118 patients in the retrospective evaluation, 59 (50%, 24 Black and 35 White) were interviewed. Black patients were more likely than White patients to report occasional, weekly, or daily solid and stool incontinence (75.0% vs 48.6%, P = 0.042; 87.5% vs 51.4%, P = 0.004, respectively) and flatal incontinence (83.3% vs 62.9%, P = 0.088).Of those prescribed fiber supplements and antidiarrheal medications, Black patients were less likely to report symptom improvement (25.0% vs 70.0%, P = 0.013; 57.1% vs 87.5%, P = 0.092, respectively, for each medication type) and ongoing regimen adherence (25.0% vs 63.3%, P = 0.013; 28.6% vs 87.5%, P = 0.035, respectively).Black patients were more likely to report impairment in daily functioning secondary to FI (83.3% vs 57.1%, P = 0.034) and were more likely to seek a follow-up visit with a health care professional that performs sacral neuromodulation (79.2% vs 28.6%, P < 0.001).</p><p><strong>Conclusions: </strong>Black patients were more likely to have severe symptoms and poorer treatment outcomes and desire future follow-up, highlighting the importance of addressing racial differences in patient preferences in FI management strategies.</p>","PeriodicalId":75288,"journal":{"name":"Urogynecology (Hagerstown, Md.)","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urogynecology (Hagerstown, Md.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/SPV.0000000000001619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Importance: Previous work identified racial disparities in access to fecal incontinence (FI) treatments. However, less is known about patient perspectives of these barriers.
Objectives: This study assessed differences in FI symptom severity and treatment utilization between Black and White patients.
Study design: This mixed-methods assessment studied adult non-Hispanic Black and White women treated for FI who either did not respond to medical therapy nor received sacral neuromodulation or did not follow up after medical therapy. Structured interviews queried patients about treatments offered and symptom severity.
Results: Of the 118 patients in the retrospective evaluation, 59 (50%, 24 Black and 35 White) were interviewed. Black patients were more likely than White patients to report occasional, weekly, or daily solid and stool incontinence (75.0% vs 48.6%, P = 0.042; 87.5% vs 51.4%, P = 0.004, respectively) and flatal incontinence (83.3% vs 62.9%, P = 0.088).Of those prescribed fiber supplements and antidiarrheal medications, Black patients were less likely to report symptom improvement (25.0% vs 70.0%, P = 0.013; 57.1% vs 87.5%, P = 0.092, respectively, for each medication type) and ongoing regimen adherence (25.0% vs 63.3%, P = 0.013; 28.6% vs 87.5%, P = 0.035, respectively).Black patients were more likely to report impairment in daily functioning secondary to FI (83.3% vs 57.1%, P = 0.034) and were more likely to seek a follow-up visit with a health care professional that performs sacral neuromodulation (79.2% vs 28.6%, P < 0.001).
Conclusions: Black patients were more likely to have severe symptoms and poorer treatment outcomes and desire future follow-up, highlighting the importance of addressing racial differences in patient preferences in FI management strategies.
重要性:先前的工作确定了在获得大便失禁(FI)治疗方面的种族差异。然而,对于患者对这些障碍的看法却知之甚少。目的:本研究评估黑人和白人患者FI症状严重程度和治疗利用的差异。研究设计:这项混合方法评估研究了接受FI治疗的非西班牙裔黑人和白人成年妇女,她们要么对药物治疗没有反应,要么接受骶骨神经调节,要么在药物治疗后没有随访。结构化访谈询问患者提供的治疗和症状严重程度。结果:回顾性评价118例患者,访谈59例(50%,黑人24例,白人35例)。黑人患者比白人患者更有可能报告偶尔、每周或每天的固体和大便失禁(75.0% vs 48.6%, P = 0.042;87.5% vs 51.4%, P = 0.004)和尿失禁(83.3% vs 62.9%, P = 0.088)。在那些处方纤维补充剂和止泻药中,黑人患者报告症状改善的可能性较小(25.0% vs 70.0%, P = 0.013;57.1% vs 87.5%, P = 0.092)和持续方案依从性(25.0% vs 63.3%, P = 0.013;28.6% vs 87.5%, P = 0.035)。黑人患者更有可能报告继发于FI的日常功能障碍(83.3%对57.1%,P = 0.034),更有可能寻求进行骶骨神经调节的医疗保健专业人员的随访(79.2%对28.6%,P < 0.001)。结论:黑人患者更有可能出现严重症状和较差的治疗结果,并希望未来随访,这突出了在FI管理策略中解决患者偏好的种族差异的重要性。